Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
about
Optimizing the management of advanced non-small-cell lung cancer: a personal viewNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignEquilibrative nucleoside transporters-A review.Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence.Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumorsA phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer.Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancerThe efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapyLaparoscopic-assisted versus open surgery for rectal cancer: a meta-analysis of randomized controlled trials on oncologic adequacy of resection and long-term oncologic outcomes.RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial.A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancerRandomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell luComparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.Novel SNP improves differential survivability and mortality in non-small cell lung cancer patientsAngiogenesis inhibitors in the treatment of non-small cell lung cancerFuture scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.Comparing effectiveness with efficacy: outcomes of palliative chemotherapy for non-small-cell lung cancer in routine practice.Bias and precision of measures of survival gain from right-censored data.Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report.Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2.Combination therapy versus single agent chemotherapy in non-small cell lung cancer.Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients.Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han populationPrediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality.Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.Bevacizumab and non-small-cell lung cancer: starving the enemy to survive.Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation
P2860
Q24656144-17CE8E55-9B4A-4F4C-84F8-147D7238BB8BQ27003440-70C30C89-C5AD-459D-A460-776C199987DCQ30244329-ECCDC954-0528-4B28-AA6C-4E59B8F24B44Q31125762-422975B2-82B7-4CEA-A286-EED2E2F19DC1Q33286793-6FD9A1B3-9BDF-4F2B-A9EE-CBA1CEE67589Q33366782-89D5F99A-9D6B-4CF7-AA1D-9855B500FFA3Q33375704-0346E8AB-91D1-412D-B9D3-25FFFCF1B9A3Q33377668-C2FA711E-095C-4997-936B-799390E7454EQ33392085-B53EBDC1-B777-4E76-9E16-BE506348D856Q33399989-E903D004-1F10-4077-B953-1A9F26B3757CQ33408330-AEED4CB2-C6E2-4D10-A0C4-1A715BD8BAA4Q33427467-1867A270-DE04-4958-B5A5-0A832A6E4EECQ33437650-3A2026BA-B41F-48EC-9B98-A5672C8951F8Q33672758-974C8798-9A46-498F-9128-ED9F7A8417D6Q33776837-476B56F3-0597-4DD9-BD37-F59F3968A30EQ33793009-889EE629-695C-4F73-A294-22BD3E11D7F0Q33847457-43AF33BA-C6A8-4F25-A52C-81FFDD441D0DQ34231106-34F2D7A8-6D3C-4B66-BE47-B1C9702E791CQ34243429-853764E2-8716-416D-A3CB-4E2A10658072Q34529840-D60170CD-F320-485C-8080-1B5DF00EA155Q34565988-FC0CC3FE-4664-47F6-A7F7-370797963094Q34913043-B6A902E1-B1E3-4EDF-A604-F674661BB94AQ35076198-295C7CC2-5B69-43EC-9768-CFE325EEDA90Q35583723-A69C669C-9EF6-4D86-A9FD-4D7BD2E8997DQ35714504-72768D58-7238-4DB3-BB01-9B5809D7C432Q35720400-9EE8C37C-FCC9-44C3-9D22-4C1637D7EE6CQ35759003-4FE46108-3F59-42DC-87E5-C7A0A6A6D76FQ35879879-CD5D2DEA-AEEF-4747-B0C1-EEC22B84A510Q35994241-BD4C3736-B4DA-466B-B297-E34403DE1269Q36128648-3B656BEB-6760-4E66-942F-8C5EA9F2E083Q36222050-7E906E77-E978-4380-A1F1-AFD5A7E01F86Q36299985-8A7BC16D-B66C-4144-AD59-B7266B6C1913Q36381261-0991434C-D648-42FC-817A-0B3A0D55F8A3Q36429474-4D89EDCC-FABF-43D0-924C-06CF72C53144Q36681506-F4FF1EA7-F6CD-43F7-A22B-E678FE4A9441Q36730313-6C059C94-1C24-47A8-B58B-88F9777A6821Q36864786-4FE3C51F-DD56-4FC2-8F9E-57F5CC6CB6A1Q36871717-0E367386-79C8-4254-8978-1D245E03868DQ36897416-0434104D-E52F-4FBB-90E9-97BBCA2E7ADAQ36985910-68596AB1-11B4-4326-A396-96A39AEE8EA3
P2860
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Efficacy of gemcitabine plus p ...... analysis of survival outcomes.
@en
Efficacy of gemcitabine plus p ...... analysis of survival outcomes.
@nl
type
label
Efficacy of gemcitabine plus p ...... analysis of survival outcomes.
@en
Efficacy of gemcitabine plus p ...... analysis of survival outcomes.
@nl
prefLabel
Efficacy of gemcitabine plus p ...... analysis of survival outcomes.
@en
Efficacy of gemcitabine plus p ...... analysis of survival outcomes.
@nl
P2093
P1433
P1476
Efficacy of gemcitabine plus p ...... analysis of survival outcomes.
@en
P2093
C Gridelli
C Manegold
G Scagliotti
J H Schiller
J P van Meerbeeck
J Vansteenkiste
M Aristides
P356
10.1016/J.LUNGCAN.2004.10.014
P577
2005-01-01T00:00:00Z